BioCardia company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

biocardia.com

Founded Year

2002

Stage

Reverse Merger | IPO

Market Cap

0.03B

Stock Price

1.63

About BioCardia

BioCardia, headquartered in San Carlos, CA, is a privately-held company developing regenerative biologic therapies to treat cardiovascular disease. The Company's products include the Helix transendocardial delivery system and the Morph steerable guide and sheath catheter portfolio. BioCardia also partners with other biotherapeutic companies to provide its Helix systems and clinical support to their programs studying therapies for the treatment of heart failure, chronic myocardial ischemia and acute myocardial infarction.

BioCardia Headquarter Location

125 Shoreway Road Suite B

San Carlos, California, 94070,

United States

650-226-0120

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing BioCardia

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

BioCardia is included in 3 Expert Collections, including Regenerative Medicine.

R

Regenerative Medicine

1,818 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

M

Medical Devices

11,170 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

H

Health IT

7,900 items

BioCardia Patents

BioCardia has filed 39 patents.

The 3 most popular patent topics include:

  • Transcription factors
  • Cardiac arrhythmia
  • Clusters of differentiation
patents chart

Application Date

Grant Date

Title

Related Topics

Status

8/27/2018

10/12/2021

Congenital heart defects, Embryology of cardiovascular system, Medical equipment, Catheters, Interventional radiology

Grant

Application Date

8/27/2018

Grant Date

10/12/2021

Title

Related Topics

Congenital heart defects, Embryology of cardiovascular system, Medical equipment, Catheters, Interventional radiology

Status

Grant

Latest BioCardia News

BioCardia to Host Q1 2022 Financial Results and Corporate Update Conference Call on May 11, 2022

May 4, 2022

Sunnyvale, California, UNITED STATES SUNNYVALE, Calif., May 04, 2022 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will report its financial results for the three months ended March 31, 2022 and provide a corporate update by conference call on Wednesday, May 11, 2022 at 4:30 PM ET. Following management’s formal remarks, there will be a question-and-answer session. Participants can register for the conference by navigating to https://dpregister.com/sreg/10166913/f2b2448b7e . Please note that registered participants will receive their dial-in number upon registration. For those who have not registered, to listen to the call by phone, interested parties within the U.S. should call 1-833-316-0559 and international callers should call 1-412-317-5730. All callers should dial in approximately 10 minutes prior to the scheduled start time and ask to be joined into the BioCardia call. The conference call will also be available through a live webcast, which can be accessed through the following link:    https://event.choruscall.com/mediaframe/webcast.html?webcastid=hA1EhbO5 , which is also available through the company’s website. A webcast replay of the call will be available approximately one hour after the end of the call through August 11, 2022 at the above links. A telephonic replay of the call will be available through May 25, 2022 and may be accessed by calling 1-877-344-7529 (domestic) or 1-412-317-0088 (international) and using access code 8381785. About BioCardia® BioCardia, Inc. , headquartered in Sunnyvale, California, is developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease. CardiAMPTM autologous and NK1R+ allogeneic cell therapies are the Company’s biotherapeutic platforms that enable four product candidates in development. The CardiAMP Cell Therapy Heart Failure Trial investigational product has been granted Breakthrough designation by the FDA, has CMS reimbursement, and is supported financially by the Maryland Stem Cell Research Fund. The CardiAMP Chronic Myocardial Ischemia Trial also has CMS reimbursement. For more information visit www.biocardia.com. MEDIA CONTACT:

BioCardia Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

BioCardia Rank

  • When was BioCardia founded?

    BioCardia was founded in 2002.

  • Where is BioCardia's headquarters?

    BioCardia's headquarters is located at 125 Shoreway Road, San Carlos.

  • What is BioCardia's latest funding round?

    BioCardia's latest funding round is Reverse Merger.

  • Who are BioCardia's competitors?

    Competitors of BioCardia include United Biomedical, Humanetics Corporation, Alexza Pharmaceuticals, Hyperion Therapeutics, Zosano Pharma and 11 more.

You May Also Like

G
GRAPP

Grand River Aseptic Pharmaceutical Packaging is a pharmaceutical contract manufacturing organization (CMO) supporting the rapid development of new biomedicines to the clinical stage in the State of Michigan. Grand River APP is the result of an alliance between Van Andel Institute (www.vai.org) and Grand Valley State University, and is operating as a non-profit, state- and federally funded corporation. Grand River APP's first aims to assure that therapeutics are properly distributed into dosage forms for all-important Phase I and Phase II human clinical trials. This process, Fill/Finish and Lyophilization, will be offered broadly to academic, nonprofit, and for-profit organizations in Michigan and across North America for liquid-based drug candidates that require vialing in an FDA-regulated aseptic clean room environment. Typical products envisioned for Grand River APP services include small molecule drugs, peptides, monoclonal antibodies, therapeutic proteins and nano-medicines. As a consequence, however, Grand River APP cannot process cytotoxic/genotoxic or virally-based candidates (e.g. viral vaccines).

A
Altheos

Altheos, Inc. is an early-stage biopharmaceutical company focused on the identification and development of promising well-differentiated novel small molecule drugs for unmet medical needs. Altheos, Inc. was co-founded in 2009 by two experienced pharmaceutical drug development executives and entrepreneurs, Henry H. Hsu, M.D. and M. (Ken) Kengatharan, Ph.D. The company is headquartered in South San Francisco, California.

Orexo Logo
Orexo

Orexo is a pharmaceutical company which focuses on identifying suboptimal therapeutic characteristics of existing products and developing more efficient and effective delivery methods for them.

U
Ulysses Pharmaceuticals

Ulysses Pharmaceuticals is dedicated to the discovery and development of safe antimicrobial agents for the treatment of severe and recurrent infections occurring in humans. The Company intends to become an industry leader in the antiinfective field through the development of new antibiotics including some acting as Trojan Horses that take advantage of essential microbial transport systems to specifically enter targeted pathogens. Ulysses concentrates on the development of advanced hit and lead compounds with promising features and characteristics that are indicative of potent antibacterial agents with potential for strong market penetration.

M
Mimetix Pharmaceuticals

Free Radical Scavengers developed from Duke's BME Department for treating and preventing diseases from occurring.

CoImmune Logo
CoImmune

CoImmune, fka Argos Therapeutics, is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases. Using biological components from each patient, the company's immunotherapies employ the patient's dendritic cells to activate an immune response specific to the patient's disease.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.